Pfizer’s evolving pipeline, partnerships, and vaccine policy pressures

Across oncology, vaccines, and metabolic disease, Pfizer is expanding its pipeline through positive trial results, new approvals, and external partnerships. The company reported favorable Phase 3 data in bladder cancer with Astellas, secured FDA approval for its BRAFTOVI regimen in first-line colorectal cancer, advanced an mRNA flu vaccine into Phase 2, and struck deals with Novavax, Beam Therapeutics, and Sciwind to bolster vaccines, gene editing, and GLP-1 obesity/diabetes assets. At the same time, broader vaccine policy is under scrutiny, with a CDC panel revisiting COVID shot safety and multiple states suing over changes to the childhood immunization schedule, creating legal and public-trust headwinds. Together, these moves show Pfizer aggressively repositioning for post-COVID growth while navigating intensifying regulatory and political oversight of its vaccine business.